The Nephroprotective Effect of TNF Receptor-Associated Factor 6 (TRAF6) Blockade on LPS-Induced Acute Renal Injury Through the Inhibition if Inflammation and Oxidative Stress.
Acute Kidney Injury
/ blood
Animals
Apoptosis
/ drug effects
Epithelial Cells
/ drug effects
Fibrosis
Gene Knockdown Techniques
Gene Silencing
Inflammation
/ pathology
Kidney Tubules
/ drug effects
Lipopolysaccharides
Male
Mice, Inbred C57BL
NF-E2-Related Factor 2
/ metabolism
NF-KappaB Inhibitor alpha
/ metabolism
Oxidative Stress
/ drug effects
Protective Agents
/ pharmacology
RNA, Small Interfering
/ metabolism
TNF Receptor-Associated Factor 6
/ antagonists & inhibitors
Up-Regulation
/ drug effects
Journal
Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063
Informations de publication
Date de publication:
13 01 2020
13 01 2020
Historique:
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
8
10
2020
Statut:
epublish
Résumé
BACKGROUND Inflammation and oxidative stress play important roles in the pathogenesis of acute kidney injury (AKI). TRAF6 functions as a signal transducer in the Toll-like receptor 4 signaling pathway. Several reports have previously implicated TRAF6 signaling in kidney pathology. Here, we investigated whether TRAF6 blockade can mitigate inflammatory responses and oxidative stress in AKI. MATERIAL AND METHODS C57BL/6 mice were injected with lipopolysaccharide (LPS, 15 mg/kg) to induce AKI. Double immunofluorescence staining of kidney tissues showed that TRAF6 was localized to renal tubular epithelial cells, and then a tubular epithelial cell line (NRK-52E) was used for in vitro analysis. TRAF6 was blocked in vitro using siRNA and in vivo using AAV2/2 shRNA. RESULTS The knockdown of TRAF6 in mice by AAV2-shTRAF6 significantly reduced renal inflammation, oxidative stress, apoptosis and kidney dysfunction in AKI. In vitro, silencing the expression of TRAF6 attenuated LPS(0.5 μg/mL)-induced inflammatory responses and oxidative stress and upregulated proapoptotic factors. Furthermore, the beneficial actions of TRAF6 blockade were closely associated with its ability to increase IkappaB-alpha and Nrf2. CONCLUSIONS Our findings provide direct evidence that TRAF6 mediates LPS-induced inflammation and oxidative stress, leading to renal dysfunction. We also show that TRAF6 inhibition is a potential therapeutic option to prevent AKI.
Identifiants
pubmed: 31929494
pii: 919698
doi: 10.12659/MSM.919698
pmc: PMC6977635
doi:
Substances chimiques
Lipopolysaccharides
0
NF-E2-Related Factor 2
0
Nfe2l2 protein, mouse
0
Protective Agents
0
RNA, Small Interfering
0
TNF Receptor-Associated Factor 6
0
NF-KappaB Inhibitor alpha
139874-52-5
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
e919698Commentaires et corrections
Type : RetractionIn
Références
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):500-14
pubmed: 25376763
Acta Physiol (Oxf). 2010 Jul 1;199(3):339-46
pubmed: 20136795
Hypertension. 2018 Dec;72(6):1301-1311
pubmed: 30571233
Transplantation. 2013 Mar 15;95(5):653-7
pubmed: 23503499
Clin J Am Soc Nephrol. 2011 Jul;6(7):1744-51
pubmed: 21734090
Sci Rep. 2019 Apr 15;9(1):6044
pubmed: 30988361
Clin Exp Pharmacol Physiol. 2013 Jan;40(1):53-5
pubmed: 23216315
Mol Nutr Food Res. 2016 Dec;60(12):2665-2677
pubmed: 27466783
Mutat Res. 2010 Aug 7;690(1-2):12-23
pubmed: 19799917
Ulster Med J. 2014 Sep;83(3):149-57
pubmed: 25484464
Immunol Rev. 2015 Jul;266(1):72-92
pubmed: 26085208
Kidney Int. 1995 Sep;48(3):674-82
pubmed: 7474651
Mol Neurobiol. 2013 Aug;48(1):190-204
pubmed: 23436141
Nephron Exp Nephrol. 2008;109(4):e109-17
pubmed: 18802373
Inflammation. 2019 Apr;42(2):637-649
pubmed: 30392071
Biomed Pharmacother. 2017 Jan;85:704-711
pubmed: 27923689
Shock. 2014 Jan;41(1):3-11
pubmed: 24346647
Clin Exp Nephrol. 2009 Feb;13(1):9-14
pubmed: 19085040
Kidney Int. 2000 May;57(5):2011-22
pubmed: 10792620
Crit Care. 2016 Mar 15;20:61
pubmed: 26976392
Kidney Int. 2011 Feb;79(3):288-99
pubmed: 20927041
Biomed Pharmacother. 2019 Sep;117:109070
pubmed: 31176164
Bioorg Med Chem. 2013 Jul 15;21(14):4011-9
pubmed: 23647822
Drug Des Devel Ther. 2018 Nov 22;12:3985-3997
pubmed: 30538426
Mediators Inflamm. 2009;2009:137072
pubmed: 20182538
Environ Health Perspect. 2002 Oct;110 Suppl 5:819-22
pubmed: 12426138